Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects

February 14, 2017 updated by: Daewoong Pharmaceutical Co. LTD.

A Randomized, Open-label, Oral Dose, Crossover Study to Compare the Safety and Pharmacokinetics Between Co-administration and Fixed Dose Combination of DWC20155 and DWC20156 in Healthy Subjects

The purpose of this study to Compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • BMI ≥ 18.5 and ≤ 27.0 kg/m2.
  • No clinically significant findings
  • Age 19-55 years at screening

Exclusion Criteria:

  • Who has allergy to investigational product

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Test / Reference Drug
DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
Drug: Co-administration of DWC20155 and DWC20156
Drug: DWJ1366 Tab.
Experimental: Reference / Test Drug
Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
Drug: Co-administration of DWC20155 and DWC20156
Drug: DWJ1366 Tab.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Maximum Plasma Concentration (Cmax)
Time Frame: 0-24 hours
0-24 hours
Area under the plasma concentration versus time curve (AUC)
Time Frame: 0-24 hours
0-24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Daewoong Pharmaceutical Co. LTD.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 30, 2016

Primary Completion (Actual)

November 26, 2016

Study Completion (Actual)

January 10, 2017

Study Registration Dates

First Submitted

October 26, 2016

First Submitted That Met QC Criteria

October 31, 2016

First Posted (Estimate)

November 2, 2016

Study Record Updates

Last Update Posted (Actual)

February 16, 2017

Last Update Submitted That Met QC Criteria

February 14, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • DW_DWJ1366002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Co-administration of DWC20155 and DWC20156

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe